21 completed, 2 terminated, 2 unknown, 1 active not recruiting. 27 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 21, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Nasal Polyps: new trials by email Literature Review of Nasal Polyps trials Research Report on Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Triamcinolone Nanocapsules After Endoscopic Nasal Surgery Triamcinolone Acetonide-Loaded Polymeric Nanocapsules, Normal Saline Nasal Irrigation - Chronic Rhinosinusitis (CRS), Nasal Polyps | Phase 2 | Recruiting | Deraya University | 50 | 2026-05-01 | 2026-07-27 |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps Verekitug (UPB-101), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | Completed | Upstream Bio Inc. | 81 | 2023-12-18 | 2026-09-18 |
| A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps TQC2731 injection, TQC2731 matching placebo - Chronic Sinusitis, Nasal Polyps | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2023-12-08 | 2025-04-16 |
| Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Dupilumab - Nasal Polyps, Asthma, Aspirin-Induced | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 17 | 2023-08-01 | 2026-08-13 |
| Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis Triamcinolone-impregnated CMC foam, Propel Stent - Chronic Rhinosinusitis, Nasal Polyps | Phase 2 / Phase 3 | Unknown | Marina Boruk | 30 | 2023-07-24 | 2023-08-01 |
| A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps 611, Placebo - Sinusitis, Nasal Polyps | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 90 | 2023-06-30 | 2024-01-12 |
| Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1) CM310, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Keymed Biosciences Co.Ltd | 56 | 2021-04-06 | 2022-06-29 |
| GB001 in Adult Participants With Chronic Rhinosinusitis GB001, Placebo - Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Completed | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | 97 | 2019-05-16 | 2021-08-23 |
| Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Ifetroban, Placebo - Nasal Polyps, Asthma, Aspirin-Induced | Phase 2 | Completed | Brigham and Women's Hospital | 38 | 2018-04-26 | 2023-07-14 |
| Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide Furosemide, Placebo - Nasal Polyps | Phase 2 | Terminated | Thomas Jefferson University | 18 | 2017-12-01 | 2023-08-30 |
| Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis Emthexate, Prednol, Mometasone Furoate - Nasal Polyposis | Phase 2 | Completed | Dokuz Eylul University | 41 | 2017-09-02 | 2020-08-31 |
| Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Benralizumab, Placebo - Chronic Rhinosinusitis (Diagnosis), Nasal Polyps | Phase 2 | Completed | Johns Hopkins University | 33 | 2017-07-01 | 2021-02-11 |
| Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis botox injection Multiguide - Chronic Disease, Nasal Polyposis | Phase 2 | Completed | Norwegian University of Science and Technology | 11 | 2016-10-01 | 2021-11-05 |
| Anti-Inflammatory Agent in Sinusitis AZ compound, Collection of Biological Specimens, Intranasal corticosteroid - Nasal Polyps | Phase 2 | Completed | Northwestern University | 43 | 2016-06-20 | 2022-05-25 |
| Study to Evaluate Multiple Doses in Patients With Nasal Polyposis AK001 low dose, AK001 high dose, Placebo - Nasal Polyposis | Phase 2 | Completed | Allakos Inc. | 40 | 2016-04-01 | 2021-01-25 |
| Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia dexpramipexole - Chronic Sinusitis With Nasal Polyps and Eosinophilia | Phase 2 | Completed | Knopp Biosciences | 20 | 2014-08-01 | 2021-05-18 |
| An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray - Nasal Polyps | Phase 2 | Completed | Sanofi | 60 | 2013-08-01 | 2017-06-26 |
| Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray - Chronic Sinusitis, Nasal Polyps | Phase 2 / Phase 3 | Completed | Intersect ENT | 100 | 2013-01-01 | 2018-07-20 |
| Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial placebo, doxycycline 100 mg - Chronic Rhinosinusitis, Nasal Polyps | Phase 2 | Completed | University Hospital, Ghent | 33 | 2011-11-22 | 2018-06-15 |
| Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps budesonide, placebo - Nasal Polyps | Phase 2 / Phase 3 | Completed | Beijing Tongren Hospital | 57 | 2010-09-01 | 2014-10-10 |
Showing 20 of 27. Sign in to see all of them.
Sinusitis (3) · Asthma (2) · Asthma, Aspirin-Induced (2) · Disease (2) · Eosinophilia (2) · Rhinosinusitis (2) · Bites and Stings (1) · Chronic Disease (1) · Nose Diseases (1) · Otorhinolaryngologic Diseases (1) · Paranasal Sinus Diseases (1) · Polyps (1) · Respiratory Tract Diseases (1) · Rhinitis (1)
Pathological Conditions, Anatomical (27) · Pathological Conditions, Signs and Symptoms (27) · Nose Diseases (26) · Otorhinolaryngologic Diseases (26) · Polyps (26) · Respiratory Tract Diseases (26) · Infections (5) · Respiratory Tract Infections (5) · Bronchial Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Respiratory Hypersensitivity (4) · Chemically-Induced Disorders (3) · Paranasal Sinus Diseases (3)
Mometasone Furoate (4) · Omalizumab (2) · Triamcinolone (2) · dupilumab (2) · Adrenal Cortex Hormones (1) · Beclomethasone (1) · Biomarkers (1) · Botulinum Toxins, Type A (1) · Budesonide (1) · Dexpramipexole (1) · Dosage Forms (1) · Doxycycline (1) · Fluticasone (1) · Furosemide (1) · Jogging (1)
University Hospital, Ghent (3) · Brigham and Women's Hospital (2) · Allakos Inc. (1) · Beijing Tongren Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Deraya University (1) · Dokuz Eylul University (1) · GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. (1) · GlaxoSmithKline (1) · Hamilton Health Sciences Corporation (1) · Intersect ENT (1) · Johns Hopkins University (1) · Keymed Biosciences Co.Ltd (1) · Knopp Biosciences (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)
United States (13) · Belgium (6) · China (4) · Germany (3) · Spain (3) · Czechia (2) · Netherlands (2) · United Kingdom (2) · Canada (1) · Egypt (1) · Norway (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1) · Ukraine (1)
Claus Bachert, MD, PhD (2) · Luo Zhang, MD (2) · Anju T Peters, MD (1) · Claus Bachert (1) · Ellen J Dutta, MD (1) · Elliot Israel, MD (1) · Jody Tversky, MD (1) · Jorge A Mazza, MD (1) · Joseph K Han, MD (1) · Keith D Forwith, MD (1) · Lars Jacob Stovner, md prof (1) · Luo Zhang (1) · Marina Boruk, MD (1)
PMID 33710614, PMID 26836729, PMID 26992115, PMID 30488542, PMID 30954643, PMID 31306495, PMID 32075470, PMID 33595845, PMID 34110505, PMID 34437720, PMID 34633904, PMID 34848949, PMID 35524339, PMID 37483544, PMID 39393433
2008 (1), 2015 (1), 2019 (1), 2023 (1), U19AI095219 (1)